• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嵌合抗原受体T细胞(CAR T)疗法的最新进展与发现为效力测定带来的新见解。

New insights on potency assays from recent advances and discoveries in CAR T-cell therapy.

作者信息

Shao Lipei, Zheng Yanyan, Somerville Robert P, Stroncek David F, Jin Ping

机构信息

Center for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD, United States.

出版信息

Front Immunol. 2025 May 8;16:1597888. doi: 10.3389/fimmu.2025.1597888. eCollection 2025.

DOI:10.3389/fimmu.2025.1597888
PMID:40406092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12095010/
Abstract

This review explores recent advances in the characteristics and manufacturing of CAR T-cell products. Traditional potency assays have been designed based on well-established CAR T-cell functionalities. However, the advent of innovative tools and methodologies has revealed a broader spectrum of important CAR T-cell characteristics that correlate with function. Furthermore, as manufacturing strategies continue to evolve, conventional potency assays may no longer fully capture the complexity of these products. Therefore, it is essential to examine these emerging characteristics and manufacturing approaches and consider the development of tailored potency assays to ensure products are fully characterized.

摘要

本综述探讨了嵌合抗原受体(CAR)T细胞产品在特性和制造方面的最新进展。传统的效力测定方法是基于已确立的CAR T细胞功能而设计的。然而,创新工具和方法的出现揭示了与功能相关的更广泛的重要CAR T细胞特性。此外,随着制造策略的不断发展,传统的效力测定可能不再能完全体现这些产品的复杂性。因此,研究这些新出现的特性和制造方法,并考虑开发定制的效力测定方法以确保产品得到充分表征至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e451/12095010/d82218c15dee/fimmu-16-1597888-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e451/12095010/c98c79f06738/fimmu-16-1597888-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e451/12095010/050669f73910/fimmu-16-1597888-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e451/12095010/d82218c15dee/fimmu-16-1597888-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e451/12095010/c98c79f06738/fimmu-16-1597888-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e451/12095010/050669f73910/fimmu-16-1597888-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e451/12095010/d82218c15dee/fimmu-16-1597888-g003.jpg

相似文献

1
New insights on potency assays from recent advances and discoveries in CAR T-cell therapy.嵌合抗原受体T细胞(CAR T)疗法的最新进展与发现为效力测定带来的新见解。
Front Immunol. 2025 May 8;16:1597888. doi: 10.3389/fimmu.2025.1597888. eCollection 2025.
2
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.免疫细胞改造:创造更智能嵌合抗原受体 T 细胞的挑战和临床方法。
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
3
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤和实体瘤:临床数据现状、当前局限性和展望。
Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003.
4
Microengineered in vitro CAR T cell screens and assays.微工程化体外嵌合抗原受体T细胞筛选与检测
Cell Syst. 2024 Dec 18;15(12):1209-1224. doi: 10.1016/j.cels.2024.11.011.
5
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.拓展嵌合抗原受体T细胞疗法的视野:从癌症治疗到自身免疫性疾病及其他领域。
Front Immunol. 2025 Feb 19;16:1544532. doi: 10.3389/fimmu.2025.1544532. eCollection 2025.
6
Tandem CAR-T cell therapy: recent advances and current challenges.串联嵌合抗原受体T细胞疗法:最新进展与当前挑战
Front Immunol. 2025 Feb 28;16:1546172. doi: 10.3389/fimmu.2025.1546172. eCollection 2025.
7
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.制造用于过继性免疫治疗的嵌合抗原受体(CAR)T细胞。
J Vis Exp. 2019 Dec 17(154). doi: 10.3791/59949.
8
Advance in chimeric antigen receptor T therapy in autoimmune diseases.自身免疫性疾病中嵌合抗原受体T细胞疗法的进展。
Front Immunol. 2025 Mar 4;16:1533254. doi: 10.3389/fimmu.2025.1533254. eCollection 2025.
9
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.嵌合抗原受体T细胞疗法的进展:抗原选择、修饰及实体瘤的当前试验
Front Immunol. 2025 Jan 6;15:1489827. doi: 10.3389/fimmu.2024.1489827. eCollection 2024.
10
Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.通过静息步骤提高临床级嵌合抗原受体工程化 T 细胞的体外效力测定。
Cytotherapy. 2019 May;21(5):566-578. doi: 10.1016/j.jcyt.2019.02.013. Epub 2019 Mar 23.

本文引用的文献

1
Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia.嵌合抗原受体(CAR)T细胞和单采产物的免疫表型可预测B细胞急性淋巴细胞白血病CD22 CAR T细胞试验中的反应。
Mol Ther. 2025 Mar 13. doi: 10.1016/j.ymthe.2025.03.019.
2
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies.用于复发或难治性B细胞恶性肿瘤的异基因现成CAR T细胞疗法。
Blood Adv. 2025 Apr 8;9(7):1644-1657. doi: 10.1182/bloodadvances.2024015157.
3
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in .
携带嵌合抗原受体整合的CD4 + T细胞淋巴瘤于……
N Engl J Med. 2025 Feb 6;392(6):577-583. doi: 10.1056/NEJMoa2411507.
4
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.慢病毒或γ逆转录病毒基因修饰T细胞疗法的长期安全性。
Nat Med. 2025 Apr;31(4):1134-1144. doi: 10.1038/s41591-024-03478-6. Epub 2025 Jan 20.
5
From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy.从体外到体内嵌合抗原T细胞制造:基于CAR-T细胞疗法的新视野
J Transl Med. 2025 Jan 4;23(1):10. doi: 10.1186/s12967-024-06052-3.
6
Accelerating CAR T cell manufacturing with an automated next-day process.通过自动化次日流程加速嵌合抗原受体T细胞(CAR T细胞)制造。
Curr Res Transl Med. 2025 Jan-Mar;73(1):103489. doi: 10.1016/j.retram.2024.103489. Epub 2024 Dec 7.
7
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.用于实体癌患者的白细胞介素-15武装的GPC3嵌合抗原受体T细胞。
Nature. 2025 Jan;637(8047):940-946. doi: 10.1038/s41586-024-08261-8. Epub 2024 Nov 27.
8
Managing allorejection in off-the-shelf CAR-engineered cell therapies.管理现成的嵌合抗原受体工程化细胞疗法中的同种异体排斥反应。
Mol Ther. 2024 Nov 26. doi: 10.1016/j.ymthe.2024.11.035.
9
Engineering CAR-T therapies for autoimmune disease and beyond.工程 CAR-T 疗法治疗自身免疫性疾病及其他疾病。
Sci Transl Med. 2024 Oct 30;16(771):eado2084. doi: 10.1126/scitranslmed.ado2084.
10
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency.CAR-T 细胞中 GLUT1 的过表达诱导代谢重编程并增强效力。
Nat Commun. 2024 Oct 6;15(1):8658. doi: 10.1038/s41467-024-52666-y.